BioNTech SE, Moderna Inc. and Johnson & Johnson are working to adapt their Covid-19 vaccines to address the omicron variant, with the German partner of Pfizer Inc. saying it could have a new version ready within 100 days if necessary.
BioNTech said Monday that it has started development in order to move as quickly as possible. The first steps of developing a new vaccine overlap with the research necessary in order to evaluate whether the shot will be needed -- a process that both it and Moderna began last Thursday as news of the new variant began to spread around the world.
